Neffy Revolutionizes Allergy Care with Express Scripts Inclusion

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company focused on improving allergy care, announced that neffy® (epinephrine nasal spray) has been added to Express Scripts’ Commercial National Formularies. This decision ensures broad access to the first FDA-approved, needle-free epinephrine nasal spray for millions of commercially insured patients nationwide.

Neffy 2 mg treats Type I Allergic Reactions, including anaphylaxis, in adults and children weighing ≥30 kg (66 lbs.). It represents a breakthrough in epinephrine delivery, offering a needle-free alternative to traditional injectors—the first such innovation in over 35 years. Neffy’s compact design allows for quick, intuitive administration and easy portability. It also boasts a 30-month shelf life and tolerates temperatures up to 122°F, enhancing usability.

Enhanced Accessibility

Sal Grausso, Head of Market Access at ARS Pharma, emphasized the significance of Express Scripts’ decision:

“This inclusion improves access to life-saving allergy treatment and underscores the importance of user-friendly solutions like neffy for severe allergic reactions.”

The quick inclusion—just nine weeks post-launch—demonstrates neffy’s strong value proposition. ARS Pharma plans to work with other payers to expand access further in the coming weeks.

Commitment to Allergy Care

The addition of neffy aligns with ARS Pharma’s mission to reduce barriers and improve outcomes for allergy patients. This groundbreaking treatment is set to redefine emergency response for anaphylaxis, empowering both patients and caregivers.